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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is closely associated to viral infection, i.e. Epstein-Barr virus 
(EBV), about 90 % of the worldwide are infected with EBV at same point of their lives. This virus is highly 
oncogenic and easily transmitted via saliva. The high level of biomarker for EBV infection can become a risk 
factor for NPC in relative’s NPC patients.  Therefore, EBV related biomarkers is needed to enable screening 
and detecting early diagnosis of NPC in endemic area. 
Objective: This study aims to analyze the role of IgA (VCA-p18+EBNA1) levels and viral load (VL) as 
screening tools for early detection in relatives of positive EBV NPC patients. Therefore, it can be used as 
predicted risk factor for NPC.  
Method: The method used in this study is cross-sectional with consecutive sampling of 50 relatives of NPC patients 
treated at the Dr. Wahidin Sudirohusodo Hospital from August 2012 to May 2013. Univariate and bivariate analysis 
and t-test are used to measure and to show the correlation of Ig A (VCA-p18+EBNA1) level and VL. 
Result: Results showed that 28 % of the NPC patients are female with an average age of 31.12±11.91.                     
Sixty-eight percent of the relatives are siblings, and most of them are Buginese tribe (58%). According to the 
risk distribution of NPC, the sampling is grouped in 3 categories i.e. high risk, intermediate risk, and low risk 
to NPC. There is 50% of the relatives of the NPC patients categorized to the intermediate risk. The IgA (VCA-
p18+EBNA1) level is significant (p=0.000) compared with the VL level (p=0.337). Sixteen percent of the high-
risk group have a normal pattern, but it still needs high awareness. Statistically, the Pearson correlation analysis 
showed a relationship but not significant. 
Conclusion: It could be concluded that IgA (VCA-p18+EBNA1) and VL level could be used as a screening 
method and early detection in relatives of NPC patients and become a predicted risk factor for NPC.  
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy which is the 
most common neoplasm in the upper aerodigestive tract. NPC is one of the 
malignancies in the field of Ear Nose Health Science (ENT) that gets a lot of 
attention because the mortality rate is still relatively high. There were approximately 
65,000 new cases and 38,000 deaths per year worldwide. Epidemiologically the 
NPC shows an interesting pattern of spread in various parts of the world, due to the 
presence of distinct geographic variations. NPC is most commonly found in the 
Mongol race, in addition to the Mediterranean, and in several races in northern 
Africa with groupings in high-risk groups (Canton, China), intermedia (North 
Africa) and low-risk groups (Western countries) (Guy de The, 2005). The incidence 
of NPC shows geographical characteristics as the highest incidence of NPC is in 
South China, where NPC is endemic malignancy in Cantonese people in 
Guangdong province of China, with an incidence of 10 to 150 per 100,000 
population per year, with an average age of 40-50 years [1]. 
In Indonesia, NPC ranks 4th among all cancers after uterine, breast, and skin 
cancer, with an incidence of around 4.7 per 100,000 inhabitants (SK Menkes, 2007). 
However, all parts of ENT in Indonesia place the NPC in the first rank of cancer in the 
head and neck area with a ratio between men and women is 2-3:1 [2]. In Yogyakarta, 
NPC is relatively higher, reaching 5.7 per 100,000 population. Dr. Dadi Hospital also 
reported the male and female ratio incidence in Makassar, South Sulawesi province, 
was about 2.6:1 [3]. The relationship between EBV and NPC was first investigated in 
1966, a rise in serum antibodies to cells infected with EBV. From several studies, It 
was obtained that there was an increase in levels of IgG and IgA antibodies to VCA 
and the increased levels of IgA antibodies did not occur in head and neck tumors other 
than NPC. Increased VCA can be seen 8-30 months before the occurrence of NPC, so 
it is very important for screening and early detection [4]. 
Serological tests have been shown to be used as early detection and follow-
up of NPC patients. In addition, EBV viral load has the power to show the 
progression of the disease [5]. EBV infects in a latent mode and it will remain 
dormant in human B cell lymphocytes for a very long time. If the immune system 
condition decreases (immunocompromised) then the episome can experience 
reactivation and then it will spur replication in individuals. Therefore, viral load 
in the circulation is expected to be used as an indicator in clinical interests. Viral 
load is the best indicator for determining NPC prognostics and is an important 
marker for progressive monitoring of recurrence of NPC patients [5]. 
NPC tends to occur more in certain races (Mongoloid) and is more 
common in men than women (2-3:1). This raises the suspicion of genetic 
factors that play a role in the etiology of this disease. The risk of NPC 
increases significantly in the first generation, the incidence is 6 times higher 
than the general population. Even NPC is also found in the second and third 
generations [6, 7] The incidence of NPC in relatives of NPC patients is 
15.5%. From the family relationship, 71% of siblings. 
Realizing the importance of early detection for the relatives of NPC patients to 
improve treatment outcome and life expectancy in Indonesia, the study analyzed the 
possibility of EBV related biomarker as the risk factor of NPC and its ability to be 
used as screening test for NPC. The author conducted this research to analyze the 
role of IgA antibody responses (VCA-p18+EBNA1) and viral load in relatives of 
patients with NPC. This study has never been done in South Sulawesi, especially in 
Makassar. This study aims to analyze the role of IgA antibody responses                           
(VCA-p18+EBNA1) and viral load in relatives of positive EBV NPC patients. 
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2. MATERIAL AND METHODS 
The study used cross-sectional design. The study was conducted at                               
Dr. Wahidin Sudirohusodo Hospital in Makassar and the UGM Medical 
Biomolecular Laboratory for 10 months, from August 2012 until May 2013. The 
study population was families of NPC patients including biological children, 
siblings, biological parents, who came to the ENT outpatient’s clinic Dr. Wahidin 
Sudirohusodo Hospital. The sample is a first or second degree relatives. Sampling 
was done by consecutive sampling based on Gaus distribution of 50 people. The 
criteria of the sample into two, they are inclusion criteria and exclusion criteria.  
Inclusion criteria are NPC patients' families, including children, and/or siblings 
and/or biological parents in part or all without complaints related to NPC, not 
limited to age, sex, ethnicity and race, at home with patients at least the last 1-2 
years, do not have a history of disturbances hemostatic and willing to be a research 
sample. Exclusion criteria are NPC patients who have been diagnosed, blood lysis 
samples, but the patients are not cooperative. 
IgA (VCA-p18+EBNA1) examination of blood serum levels was 
analyzed by enzyme-linked immunosorbent assay (ELISA) method using 
synthetic peptide immunodominant epitope protein VCA-p18 and EBNA1. 
Examination of viral load through DNA isolation by polymerase chain 
reaction (PCR) with Boom method, the results of concentration will be 
obtained after light cycler PCR runs 45 minutes. 
3. RESULT 
During the study period from August 2012 to May 2013, a research was 
conducted to look at IgA antibody responses (VCA-p18+EBNA1) and viral 
load of 50 family members of nasopharyngeal carcinoma patients. Blood 
tests (whole blood) were used to assess IgA (VCA-p18+EBNA1) and 
plasma examination to assess viral load. 
3.1 Sample General Characteristics 
Table 1. Characteristics of Research Samples   
Characteristics n    % 
Gender 
Male 
Female 
 
22 
28 
 
44.0 
56.0 
Age 
<20 years old 
20-29 years old 
30-39 years old 
40-49 years old 
≥50 years old 
 
8 
17 
13 
8 
4 
 
16.0 
34.0 
26.0 
16.0 
8.0 
Family relationship with NPC patients 
Child 
Sibling 
Mother 
Grandchild 
 
34 
13 
2 
1 
 
68.0 
26.0 
4.0 
2.0 
Ethnic Group 
Bugis 
Toraja 
Makassar 
Raha 
Bali 
 
29 
9 
10 
1 
1 
 
58.0 
18.0 
20.0 
2.0 
2.0 
Out of 58 patients, we found 56% of the NPC patients were female (n=28), the 
average age of families with NPC patients was 31.12±11.91 where the youngest 
was 13 years old, and the oldest was 66 years old. 34 of the samples are biological 
children of the patients (68%), 13 samples are the siblings (26%), and 2 samples are 
biological mother of the patients (4%), and 1 of them is the biological grandchild of 
the patient (2%). While most tribes are Bugis, 29 people (58%), followed by 
Makassar tribe, 10 people (20%), Toraja tribe, 9 people (18%), and lastly Raha and 
Bali, 1 person (2%) who have long resided due to migration on Sulawesi. 
Table 2. Grouping of Families of NPC Patients Based on histopathological overview 
of NPC Patients 
Histopathology View    n % 
Type II 6 12.0 
Type III 44 88.0 
Total 50 100.0 
In this study we found that 88% of the samples (n=44) were relatives 
of WHO type III NPC patients then followed by WHO type II (n=6). 
The distribution of families of NPC patients based on the stage of NPC 
patients according to TNM-UICC 2010 had the most stage IVB 16 people 
(32%), then stage III 13 people (26%), stage IIB 7 people (14%), stage IVA 
6 people (12%), stage II A 4 people (8%) and the last same number stadium 
I and IVC which is 2 people (4%) can be seen in table 3. 
Table 3. Distribution of NPC patients based on the NPC stage 
Staging of NPC Total % 
Stage I 2 4.0 
Stage IIA 4 8.0 
Stage IIB 7 14.0 
Stage III 13 26.0 
Stage IVA 6 12.0 
Stage IVB 16 32.0 
Stage IVC 2 4.0 
Total 50 100.0 
3.2 IgA Examination Results (VCA-p18+EBNA1) 
From the results of examination of levels of IgA (VCA-p18+EBNA1) using 
the ELISA method in 50 family members of NPC patients found in families of NPC 
patients above 28 people Cut Cut Value (CoV) (56%) can be seen in table 4.  
Table 4. IgA (VCA-p18+EBNA1) levels in families with NPC patients  
IgA (VCA-p18+EBNA1) n  % 
>CoV 28 56.0 
≤CoV 22 44.0 
Total 22 100.0 
*Cut-off Value=0.32 
Graphic 1. Level of IgA (VCA-p18+EBNA1) in a family with NPC 
Based on graph 1 there are 26 samples showing positive results for 
checking IgA (VCA-p18+EBNA1), 2 samples are in the, and 22 samples 
show results below Cut-off Value (CoV). 
Table 5.  Relationship of age, sex and family status of people with NPC with 
IgA (VCA-p18+EBNA1) 
Variable 
IgA (VCA-p18+EBNA1) 
>CoV ≤CoV 
n % n % 
Age     
<20 years old 3 10.71 5 22.7 
20-29 years old 9 32.1 8 36.4 
30-39 years old 7 25.0 6 27.3 
40-49 years old 6 21.4 2 9.1 
≥50 years old 3 10.7 1 4.5 
Gender     
Male 10 35.7 12 54.5 
Female 18 64.3 10 45.5 
Family Relation 
Child 
 
17 
 
60.7 
 
17 
 
77.3 
Sibling 8 28.6 5 22.7 
Mother 2 7.1 0 0.0 
Grandchild 1 3.6 0 0.0 
Table 5 shows that in the age group of 20-29 years the most shows 
above CoV there are 9 people (32.1%) while the highest sex above CoV is 
female 18 people (64.3%). Based on the most family relationships above, 
CoV is 17 biological children (60.7%). 
3.3 Viral Load Check 
From the results of viral load examination in 50 family members of 
NPC patients, 13 people showed results above the Cut-off Value (CoV).               
In table 6, there are 5 family members (4 biological and 1 sibling) with 
results above CoV, but when compared with the results of IgA (VCA-
p18+EBNA1) the results are below CoV. 
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Table 6. Number of EBV DNA and IgA Levels (VCA-p18+EBNA1) in 
families with NPC patients 
No 
Sample 
Code 
Family Relation 
with NPC patients 
Total of EBV DNA 
per ml of blood 
Level of IgA                 
(VCA-p18+EBNA1) 
1 NWB 08 Child 247.600 0.3260 
2 NWB 09 Child 7.678.000 0.6520 
3 NWB 12 Child 405.600 2.3759 
4 NWB 31 Child 263.000 0.1145 
5 NWB 32 Child 135.100 0.0580 
6 NWB 38 Sibling 125.180.000.000 0.0205 
7 NWB 42 Child 17.092.000 0.1710 
8 NWB 48 Child 334.200 0.1030 
9 NWB 57 Sibling 408.000 2.4065 
10 NWB 58 Sibling 421.800 2.3910 
11 NWB 59 Child 278.400 0.5335 
12 NWB 60 Child 6.732 2.1365 
13 NWB 70 Mother 21.400 0.8680 
Graphic 2. Amount of EBV DNA per ml of blood 
 
The range of EBV DNA detected in the sample is 6.732 X 103-1.25 x 
1010. In 13 patients whose EBV DNA was detected all were above CoV 
(2,000 EBV DNA per ml of blood). 
3.4 IgA (VCA-p18 + EBNA1) and Viral Load Examination Results 
Table 7. Risk distribution of NPC based on IgA (VCA-p18+EBNA1) and VL 
Category Total  % 
High IgA (VCA-p18+EBNA1) and VL  8 16.0 
High IgA (VCA-p18+EBNA1) low VL  20 40.0 
Low IgA (VCA-p18+EBNA1) high VL 5 10.0 
Low IgA (VCA-p18+EBNA1) and VL  17 34.0 
Total 50 100.0 
Table 7 showed that the group with high IgA (VCA-p18+EBNA1) and low 
viral load was the group with highest number with 20 people (16%). It then 
followed respectively by the group with low IgA (VCA-p18+EBNA1) and viral 
load with 17 people (34%), high IgA group (VCA-p18+EBNA1) and  viral load 
with 8 people (16%) and the last group was low Ig A (VCA-p18+EBNA1) and 
high viral load with 5 people (10%). 
Table 8. Risk distribution of NPC based on IgA (VCA-p18+EBNA1) and VL 
Category  n % 
High-risk NPC 8 16.0 
Intermediate risk NPC 25 50.0 
Low-risk NPC 17 34.0 
Total 50 100.0 
Table 8 group categories are reduced to 3 groups, namely the high risk 
group NPC, intermediate risk NPC and low risk NPC where the highest in 
the intermediate risk group of the NPC as many as was 25 people (50%), 
then the low risk group NPC was 17 people (34%) and the last high risk 
group NPC was 8 people (16%). 
Table 9. Risk of NPC according to gender in the relatives of NPC patients 
Table 9 shows that female was found higher in the intermediate and 
low-risk NPC group (60% and 52.9%, respectively), while male and female 
were found to be equally in the high-risk NPC group. 
Table 10. Distribution of NPC risk according to age 
Table 10 shows the distribution of NPC risk according to patient’s age. 
It was found that intermediate-risk group was found to be the most 
commonly found (n=10; 40%) between the ages of 20 to 29 years old, 
followed by low-risk group (35.3%) within the same age range. 
Table 11. Risk distribution of NPC based on family relationships 
 
In table 11 the most in the three risk groups of NPC were biological 
children with the most intermediate risk group with 16 people (64%) 
followed by the low-risk group 13 people (76.5%) and the last high-risk 
group 5 people (62.5 %).  
Table 12. IgA (VCA-p18+EBNA1) and Viral Load levels in families with 
NPC patients 
Family with NPC patients n Average ±SD P 
IgA (VCA-p18+EBNA1) 
Viral Load 
50 
13 
0.9261 ± 0.9557 
9.631.330.141±34.718.054.846.927 
0.000 
0.337 
*CoV IgA=0.32, CoV EBV Viral Load=2000 EBV DNA per ml blood 
Table 12 shows that the levels of IgA (VCA-p18+EBNA1) in the 
families of NPC patients were very significant (p=0,000), whereas with viral 
load levels there were not have significant differences (p=0.337).  
Table 13. Results of Pearson correlation analysis between IgA  (VCA-p18+EBNA1) 
and EBV Viral Load in families with NPC patients 
 EBV Viral Load 
Ig A (VCA-p18+EBNA1) R -2.75 
P 0.363 
N 13 
From the results above, a significant value of 0.363 which indicates that 
there is no correlation between IgA (VCA-p18+EBNA1) and the family 
viral load of NPC patients with Pearson correlation value of -2.75 shows a 
negative correlation with weak correlation strength. There is a correlation 
but not significant or statistically not meaningful, but there is a relationship. 
4. DISCUSSION 
Based on data from various world populations, the highest incidence 
rate of NPC is in Guangdong, China where (150/100,000 population).               
The incidence rate in Indonesia is 4.7/100,000 population, especially in 
Makassar 5/100,000 population and usually occurs more in men with age 
productive within the productive age between 40-50 years. This study took 
a family sample of NPC patients because in the previous study it was said 
that the incidence of the risk of NPC was quite high (6 times higher than the 
general population) in the first generation [7, 9]. Based on the characteristics 
of the average age of the families of NPC patients, 31.12±11.91 showed a 
trend below the productive age which was found in the age range of 20-29 
years as many as 17 people (34%) with the youngest age of 13 years and the 
oldest 66 years. The most incidence based on gender was female with a ratio 
of 1.2:1, this is slightly different from previous studies where more men 
were obtained with a ratio of 1.3:1 and 0.8:1 [10]. This could be caused by 
the samples were dominated by female. The majority of the tribe is Bugis, 
Gender 
High Risk Intermediate risk Low risk Total 
n % n % n % n % 
Male 4 50.0 10 40.0 8 47.1 22 44.0 
Female 4 50.0 15 60.0 9 52.9 28 56.0 
Total 8 100.0 25 100.0 17 100.0 50 100.0 
Age 
High Risk Intermediate risk Low risk Total 
n % n % n % n % 
<20 y.o 1 12.5 3 12.0 4 23.5 8 16.0 
20-29 y.o 1 12.5 10 40.0 6 35.3 17 34.0 
30-39 y.o 1 12.5 8 32.0 4 23.5 13 26.0 
40-49 y.o 4 50.0 2 8.0 2 11.8 8 16.0 
≥50 y.o 1 12.5 2 8.0 1 5.9 4 8.0 
Total 8 100.0 25 100.0 17 100.0 50 100.0 
Family 
Relation 
High Risk Intermediate risk Low risk Total 
n % n % n % n % 
Child 5 62.5 16 64.0 13 76.5 34 68.0 
Sibling 2 25.0 7 28.0 4 23.5 13 26.0 
Mother 1 12.5 1 4.0 0 0.0 2 4.0 
Grandchild 0 0.0 1 4.0 0 0.0 1 2.0 
Total 8 100.0 25 100.0 17 100.0 50 100.0 
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29 people (58%), almost the same as previous studies about patients and 
families of people with NPC in Makassar [11, 12]. 
Based on family relations with NPC patients in this study, the majority 
were 34 children (68%) followed by 13 siblings (26%) and biological 
parents in this case the mother contained 2 people (4%). This is almost the 
same as previous studies regarding families of NPC patients where most of 
the biological children were 48.6%, siblings 34.3% and biological parents 
17.1%. However, in contrast to previous research [10], the highest family 
relationships in a row were 54.8% siblings, biological parents 49.3% and 
biological children 6.7% from a total sample of 929 people. 
The families of NPC patients based on histopathological sensation of 
NPC patients according to WHO 1979 were the most WHO type III 44 
people (88%) followed by WHO type II as many as 6 people (12%) and 
could not be found at all WHO type I, according to those issued by [11, 13]. 
WHO type II and III histopathologies are almost 100% associated with 
Epstein-Barr virus infection [14-16]. 
In the distribution of families of NPC patients based on the stage of NPC 
patients according to TNM-UICC 2010 most were stage IV B 16 people (32%) 
followed by stage III 13 people (26%), inversely with previous studies [12, 17] 
where most stage III was obtained 48.6%, then stage IV 40%. Thus, it indicates 
that almost the majority of NPC patients come to treatment in an advanced 
stage, which causes a prognosis of treatment and poor life expectancy. 
Therefore, early screening and detection of NPC are needed through a pattern 
of biomolecular approaches to Epstein-Barr virus. 
From the risk distribution of NPC based on examination of IgA                 
(VCA-p18+EBNA1) and viral load, we grouped it into 3 categories of 
groups. They are high-risk NPC where IgA (VCA-p18+EBNA1) and viral 
load are high, intermediate risk NPC with IgA (VCA-p18+EBNA1) is high 
and viral load is low, and IgA (VCA-p18+EBNA1) is low and the last high-
risk viral load is low-risk KNF where IgA (VCA-p18+EBNA1) and viral 
load are low. The most intermediate risk group is 25 people (50%) with the 
highest female gender in both the intermediate risk and low-risk groups 
(60% and 52.9%). While the age range was the most at the age of 20-29 
years in the intermediate risk group (40%) and biological children held the 
highest rank in the intermediate risk group (64%). In this intermediate risk 
group, there is high IgA (VCA-p18+EBNA1) and low viral load where the 
possibility of the virus is not reactivated in latent infection. So that this 
group is a carrier where the virus does not appear and is not expressed 
whereas low IgA (VCA-p18+EBNA1) and high viral load are not likely to 
be NPC because it is not IgG, so it is not a risk factor. 
4.1 Levels of IgA (VCA-p18+EBNA1) and Viral Load levels in 
families with NPC patients in Makassar 
The results of the examination of IgA (VCA-p18+EBNA1) levels by the 
ELISA method in 50 family members of NPC patients were found above 28 
people in CoV (56%) and 13 people in the viral load above CoV with an 
average of 26%. 0.9261±0.9557 at levels of IgA (VCA-p18+EBNA1) and at 
an average viral load level of 9,631,330,141±34,718,054,846,927. The results 
of the levels of IgA (VCA-p18+EBNA1) turned out to be very significant with 
a value of p=0.000 (p<0.05) compared to the results of viral load levels which 
turned out to be not significant with p=0.337 (p>0.05). 
Of the 50 samples, there were 8 family members (16%) who were high 
both IgA (VCA-p18+EBNA1) and viral load levels (high-risk category of 
KNF). In accordance with the table of possible z-values of observations, 
they are still within the normal distribution limit but need to be vigilant for 
those in the high-risk category because they tend to have a higher risk and 
require a shorter time to become KNF. Because of that more rigorous 
follow-up with careful clinical examination is needed because most 
sufferers in countries with high NF incidence such as Indonesia only come 
to hospitals for treatment in stage III or IV. Looking at Wai's research, Tong 
Ng et al. (2005) examined 929 samples from families of NPC patients who 
obtained positive IgA VCA in 84 people and carried out a follow-up period of 
6-32 months which turned out to be 9 people (10.7%) [10]. Lo's research, S et 
al. (2004) found that 66 normal people with positive Ig VCA were followed 
for <4 years, only 1 person (2%) developed NPC [18]. In Xiaohong's research 
(Rose) Yang et al. (2005) in Taiwan from 100 samples of families of NPC 
patients only 1 was detected by NPC [6]. While research by Tiwawech, Danai 
(2008) in Thailand, there are 122 control samples obtained positive 
IgA/EBNA1 in 5 people (4.10%). Data from Malaysia found that 2 patients 
with stage IIB found high viral load DNA, 2 other patients with high stage IVB 
and IIB persistent IgA VCA titers but low viral load DNA. 
Pearson correlation analysis between IgA (VCA-p18+EBNA1) levels 
and EBV viral load in families with NPC patients despite showing a negative 
correlation with weak correlation strength but statistically showed a 
relationship although not significant. This can be caused by differences in 
gene factors, differences in environmental factors [19] and endurance. 
Differences in the profile of IgA (VCA-p18+EBNA1) and viral load are 
likely caused by genetic variation of hosts and viruses. Host variations can 
be caused by variations in MHC class I/HLA, while variations in viruses are 
LMP. Another host aspect that might play a role besides genetics is the 
difference in eating habits. 
Viewed from the whole data indicate that the family of NPC patients is 
a high-risk group for the occurrence of NPC, and this finding supports the 
genetic factor hypothesis, so it is important to do early screening and 
detection for family members of NPC patients. 
5. CONCLUSION 
The conclusion of the study is IgA (VCA-p18+EBNA1) levels were 
statistically more significant than viral load levels. Although it shows a negative 
correlation with a weak correlation between IgA (VCA-p18+EBNA1) and viral 
load statistically there is a relationship even though it is not significant.  IgA 
(VCA-p18+EBNA1) levels with viral load can be a method of screening and 
detection for family members of NPC patients. Sample for screening and early 
detection of patient’s families is first-degree relatives only, and addition form of 
more detailed data patient’s family. Periodic follow-up family members with IgA 
levels (VCA-p18+EBNA 1) and viral load above the cut-off value. Further 
research are is need longitudinally with a larger number of samples in order to 
get better results. 
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